Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12766236 | 1.00 | LMNA (0.40) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL24377733 | 1.00 | LMNA (0.40) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL13213433 | 0.89 | FOLH1 (0.46) | LMNACYP2C9RNPEPFOLH1ALDH1A1 | |
| SCHEMBL19729236 | 0.86 | LMNA (0.41) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL17431202 | 0.86 | LMNA (0.41) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL24172616 | 0.85 | RNPEP (0.36) | LMNACYP2C9RNPEP | |
| SCHEMBL19386700 | 0.84 | CYP2C9 (0.36) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL21216215 | 0.83 | METAP2 (0.33) | — | |
| SCHEMBL21677992 | 0.82 | RNPEP (0.39) | LMNACYP2C9RNPEPTSHRFOLH1 | |
| SCHEMBL21677920 | 0.82 | RNPEP (0.39) | LMNACYP2C9RNPEPTSHRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023028338-A2 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20200046625-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-9771392-B2 | Compounds which inhibit neuronal exocytosis | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9393187-B2 | Peptide compounds that inhibit neuronal exocytosis | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150071974-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | LUBRIZOL ADVANCED MATERIALS, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8946166-B2 | Peptide-based compounds and compositions which inhibit muscle contraction | LIPOTEC, S.A. (ES) | 2015-02-03 | — | — | US | disclosed |
| US-8653278-B2 | Isoform selective HDAC inhibitors | GEORGETOWN UNIVERSITY (US) | 2014-02-18 | — | — | US | disclosed |
| US-20120121675-A1 | COMPOUNDS WHICH INHIBIT MUSCLE CONTRACTION | LIPOTEC, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
| US-20110003943-A1 | Supported Oxidation Reactants, Process for their Preparation and Uses Thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2011-01-06 | — | — | US | disclosed |
| US-20100196502-A1 | Isoform Selective HDAC Inhibitors | GEORGETOWN UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-20080220497-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS LLC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | LMNA 2955/4885CYP2C9 4727/4885RNPEP 120/4885 |
| US-20200046625-A1 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | CUTA, MCOLN3, MC3R | LMNA 846/4885CYP2C9 2204/4885RNPEP 961/4885 |
| US-20110003943-A1 | Supported Oxidation Reactants, Process for their Preparation and Uses Thereof | DAO, MTR, MET | LMNA 4145/4885CYP2C9 1249/4885RNPEP 526/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | LMNA 3307/4885CYP2C9 2381/4885RNPEP 178/4885 |
| US-20120121675-A1 | COMPOUNDS WHICH INHIBIT MUSCLE CONTRACTION | ATP2A3, MYLK2, MYL6 | LMNA 1737/4885CYP2C9 2611/4885RNPEP 1406/4885 |
| US-20080220497-A1 | Modulation of protein functionalities | C1QBP, SERPINA6, CD2BP2 | LMNA 2302/4885CYP2C9 4610/4885RNPEP 266/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | LMNA 2973/4885CYP2C9 4673/4885RNPEP 133/4885 |
| US-20100196502-A1 | Isoform Selective HDAC Inhibitors | HDAC5, HDAC6, HDAC3 | LMNA 2163/4885CYP2C9 4014/4885RNPEP 3307/4885 |
| US-20150071974-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | SLC18A2, SLC18A1, ATP6V1B2 | LMNA 4001/4885CYP2C9 2163/4885RNPEP 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.